Clinical Trials

IST-2015-100730-Phase I Study of Carfilzomib-based Chemotherapy mobilization for autologous stem cell transplantation in multiple Myeloma


Study ID
Hackensack UMC/Amgen IST-Pro2018-0531

NCT Number
NCT03909412 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0531

Principle Investigator
Dr. David Vesole

Phase
I

Sponsor
Amgen Corporation


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now